Species
Dog
Area of Study
Cardiology
Purpose of Study
- Characterize oral spironolactone absorption, metabolism, and clearance in dogs diagnosed with CHF using a population pharmacokinetic (PK) approach compared to previously studied healthy dogs.
- Correlate PK parameters with ultrasonographic measures of venous congestion from heart disease. This study will reveal whether the absorption, metabolism, and clearance of oral spironolactone are altered in dogs with CHF, and findings of this study will offer recommendations for clinicians to enhance medication dosing strategies and improve treatment efficacy in dogs with CHF.
Eligibility
This study will enroll client-owned dogs diagnosed with congestive heart failure (CHF).
Procedures
During the study, you may expect the following procedures:
- Comprehensive review of medication history (including spironolactone dosing and administration timing), assessment of
clinical signs, blood collection and a physical examination. - Echocardiography and point of care ultrasound (POCUS) will also be performed to evaluate the severity of heart disease and measures of venous congestion.
Costs and Compensation
There is no cost to you for your dog’s participation in this study. All procedures related to the study will be covered. However, there is no additional financial compensation for participating.
For further information about the study, contact Dr. Kristen Poplawski at 515-294-4900